ZIVOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Zivo Bioscience, Inc.
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$6.80+0.30 (+4.62%)
Close on Oct 19, 2026
- Market cap
- $25.96M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2024
Gross margin
31.1%
Operating margin
-8498.9%
Net margin
-8513.4%
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +468.6% | – | – | – | |
| Gross profit | +321.6% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | 73.0% | 75.2% | 983.9% | |
| Return on assets | -6633.7% | -2947.9% | -1217.4% | |
| Current ratio | 0.01 | 0.04 | 0.80 | |
| Debt to equity | – | 0.00 | -0.23 | |
| Net debt to EBITDA | – | 0.04× | – | |
| Interest coverage | 1273.5× | – | – | |
| Diluted shares | 2M | 3M | 3M |
Cash use needs five years of cash flow figures
Zivo Bioscience does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-8513.4%
×Asset turnover0.14×
×Equity multiplier-0.81×
=Return on equity, FY2024983.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -8513.4% | 0.14× | -0.81× | 983.9% |
| FY2023 | -28127.2% | 0.02× | -1.21× | 701.8% |
| FY2020 | -45528.6% | 0.07× | -0.03× | 92.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
3of 8 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero-$13.38M
- Cash generatingOperating cash flow above zero-$4.31M
- Return on assets improvedROA up on the prior year-366.3% → -2408.6%
- Earnings backed by cashOperating cash flow above net income-$4.31M vs -$13.38M
- Less leverageLong-term debt to assets fell– → 7.1%
- Better liquidityCurrent ratio rose0.15 → 0.80
- No dilutionShare count did not rise2M → 3M
- Gross margin improvedGross margin up on the prior year41.99% → 31.14%
- More efficientAsset turnover rose0.01 → 0.28